



Oncology



**Li-Yuan, Bai**  
M.D., Ph.D

China Medical  
University Hospital

- Director - The Division of Hematology and Oncology, China Medical University Hospital

### Highlights

- Leading PI (Phase II Trial of Biweekly S-1, Leucovorin and Gemcitabine (GSL) in Elderly Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma)
- Leading PI (Phase 2 Study of Nanoliposomal Irinotecan (nal-IRI), PEP02, MM-398, Onivyde®) with 5-FU and Leucovorin in Squamous Cell Carcinoma (SCC) of Head & Neck and Esophagus after Prior Platinum-based Chemotherapy or Chemoradiotherapy)

Research Area(s) of Interest

Gastric cancer, pancreatic cancer, Biliary tract cancer, neuroendocrine tumor, Gastrointestinal stromal tumor, lymphoma



Oncology



**Ann-Lii, Cheng**  
M.D., Ph.D

National Taiwan  
University Hospital

- Distinguished Professor - Department of Internal Medicine, National Taiwan University College of Medicine
- Superintendent - National Taiwan University Cancer Center Hospital

### Highlights

- Prof. Cheng has been the Global leading PI (IMbravel150 · KEYNOTE-240 · ORIENTAL · APEC · RESORCE...) and Steering committee member in many global trials.
- He contributed significantly to all three first-line treatment of advanced hepatocellular carcinoma(HCC) – sorafenib, lenvatinib, and the combination of atezolizumab and bevacizumab ( IMbravel150, New England Journal of Medicine, 2020, 382(20):1894-1905.)

Research Area(s) of Interest  
Medical Oncology, HCC



Oncology



**Tsu-Yi, Chao**  
M.D.

Taipei Medical University  
Shuang-Ho Hospital

- Professor - Research Institute of Clinical Medicine, Taipei Medical University
- Chief - Division of Hematology/Oncology, Shuang-Ho Hospital, Taipei Medical University


### Highlights

- Participated in over 120 investigations ranging from Phase I to Phase IV studies since 1997.
- Influential trials including: capecitabine (Xeloda) in the treatment of MCC, trastuzumab (Herceptin) in HERA trial and BCIRG 005/006 trials, gefitinib (Iressa) in IPASS trial...etc.
- Sitting in the Asia-Pacific regional steering committee of MonarchE study. Also has been the steering committee member of Asia- Pacific Breast Initiatives I and II studies.
- Currently involved in early phase trials for anti-cancer drug development with novel mechanisms.

Research Area(s) of Interest  
Hematology and Oncology,  
Translational studies



Oncology



**Chao-Hua, Chiu**  
M.D.

Taipei Veterans  
General Hospital

- Director - Division of Thoracic Oncology, Department of Chest Medicine, Taipei Veterans General Hospital
- Executive Secretary - Human Research Protection Center, Taipei Veterans General Hospital

### Highlights

- Successfully managed the accreditation process of the Association for the Accreditation of Human Research Protection Programs (AAHRPP) in 2016 and 2019.
- Actively participates in clinical trials as a senior investigator in lung cancer.

Research Area(s) of Interest  
Lung cancer



Oncology



**Tsai-Yun, Chen**  
M.D.

National Cheng Kung  
University Hospital

- Director - Clinical Trial Center, National Cheng Kung University Hospital

### Highlights

- Early phase drug development

Research Area(s) of Interest  
Hemato Oncology,  
Stem Cell Transplantation and Coagulation,  
Cancer treatment and consultation,  
Hematological Diseases



Oncology



**Ming-Feng, Hou**  
M.D.

Kaohsiung Medical  
University Chung-Ho  
Memorial Hospital

- Superintendent - Kaohsiung Medical University Chung-Ho Memorial Hospital

### Highlights

- Specializes in breast cancer diagnosis, surgery, chemotherapy, and molecular oncology
- The third President of the Breast Cancer Society of Taiwan.
- Dr. Hou's research group joint in international breast cancer research with the Academia Sinica and Tri-service General Hospital, and the related result was published in Nature.

Research Area(s) of Interest  
Breast Cancer



Total Number of Clinical Trials Conducted



Total Publications



Ministry of Health and Welfare  
www.mohw.gov.tw



Center for Drug Evaluation, Taiwan  
www.cde.org.tw



Oncology



**Ming-Mo, Hou**  
M.D.

Chang Gung Memorial Hospital, Linko

- Medical Oncologist - Chang Gung Memorial Hospital, Linko

Highlights

- Principal Investigator at CGMH site: NCT02407990 (Advanced tumors), NCT02699515 (MSB0011359C (M7824)), NCT02648490 (advanced solid cancers), NCT01658878 (CheckMate 040), NCT02151357 (Advanced Solid Tumor), NCT03143153 (CheckMate 648), NCT03298451 (HIMALAYA)
- Advisory board for pembrolizumab in advanced MSI-H colon cancer, nivolumab/ipilimumab in for advanced esophageal cancer and nivolumab/ipilimumab in advanced HCC

Research Area(s) of Interest

Early phase trial, clinical trials of HCC, esophageal cancer, gastric cancer, cholangiocarcinoma, pancreatic cancer



Oncology



**Chiun-Sheng, Huang**  
MD, PhD, MPH

National Taiwan University Hospital

- Chairman and Professor - Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
- Director - Breast Care Center, National Taiwan University Hospital
- Chairman of Taiwan Breast Cancer Consortium(TBCC)

Highlights


- Leading TBCC, an academic research organization, composed of wide-experienced centers with large patient pool, conducting trials for domestic and international pharmaceutical companies, and research institutions
- Global study chair of a multi-national randomized trial of cancer vaccine in metastatic breast cancer and another trial of neoadjuvant biosimilar trastuzumab in early breast cancer
- Member of Steering Committee in several global trials investigating anti-Her-2 target therapies (LUX Breast 1, Kristine, Katherine) leading to FDA approval of T-DM1 in early breast cancer, anti-PDL1 antibody (NeoTrip, AptNeo) and CDK4/6 inhibitors (MonarchE, Natile) for breast cancer.
- Published 200 papers in related fields of breast cancer
- Member of the St. Gallen International Breast Cancer Consensus Panel since 2017

Research Area(s) of Interest

Breast Cancer, Breast Ultrasound, Breast Cancer Clinical trial



Oncology



**Chih-Hsi, Kuo**  
M.D.

Chang Gung Memorial Hospital, Linko

- Associate Professor - Department of Thoracic Oncology, Chang Gung Memorial Hospital

Highlights

- Principal Investigator at CGMH site: NCT03539536 (Telisotuzumab Vedotin (ABBV-399), national ranking top 1, patient recruitment), NCT02453282, NCT04294810, NCT03728556

Research Area(s) of Interest

Thoracic Oncology, NSCLC



Oncology



**Kang-Yun, Lee**  
M.D., Ph.D

Taipei Medical University Hospital

- Dean - Office of Human Research, Taipei Medical University

Highlights

- Member of steering committee on ARDS, TaiGen Biotechnology.
- More than 4 trials achieve the top enrollment site in Taiwan or in the world. (2016-present)
- Acting Chief and Head of Investigator of global clinical trial. (2016-present)
- Receive the glory of "first patient in" in Taiwan/Asia many times.
- 2019 Excellent Clinical Trial Leader Award, Taipei Medical University
- Specialty :
  - Airway disease
  - Lung cancer
  - Other pulmonary disease

Research Area(s) of Interest

Thoracic Medicine



Oncology



**Her-Shyong, Shiah**  
M.D.

Taipei Medical University Hospital

- Assisted Professor - Graduate Institute of cancer Biology and Drug Discovery, Taipei Medical University

Highlights

- Participated in over 120 investigations ranging from Phase I to Phase IV studies since 1994.
- First one to find the HBV reactivation in the targeted therapy (everolimus) and being put into warning box of package insert
- Help Hansoh Pharma with the NDA of almonertinib receive marketing authorization in China. Conducting numerous Phase I trials of first-in-human and first-in-class

Research Area(s) of Interest

Hematology and Oncology



Oncology



**Wu-Chou, Su**  
M.D.

National Cheng Kung University Hospital

- Director - Department of Internal Medicine, National Cheng Kung University Hospital
- Director - Center of Applied Nanomedicine, National Cheng Kung University
- Chief - Division of Hematology/Oncology, Department of Internal Medicine, National Cheng Kung University Hospital

Highlights

- Global leading PI
- Early phase drug development

Research Area(s) of Interest

Hemato Oncology, Cancer Drug Resistance, Cytokine Signal Transduction, Nanomedicine





## Oncology



**Jaw-Yuan, Wang**  
M.D., Ph.D

Kaohsiung Medical  
University Chung-Ho  
Memorial Hospital

- Vice Superintendent - Kaohsiung Medical University Chung-Ho Memorial Hospital

### Highlights

- Specializes in digestive surgery · oncology molecular biology · surgical nutrition · microbiota
- Dr. Wang is an editor in several prestigious international Journals, e.g World Journal of Gastroenterology, Asian Journal of Surgery, Kaohsiung Journal of Medical Sciences and Oncology Letters.
- He was the PI of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan, between 2012 and 2018.
- Since 2018 he hold the position of President of the Society of Colon and Rectal Surgeons, Taiwan.

### Research Area(s) of Interest

Digestive surgery · oncology molecular biology · surgical nutrition · microbiota

| > 30 | > 310

## Oncology



**Chia-Jui, Yen**  
M.D., Ph.D

National Cheng Kung  
University Hospital

- Deputy Director - Clinical Trial Center, National Cheng Kung University Hospital

### Highlights


- Early phase drug development

### Research Area(s) of Interest

Hematological Diseases, Oncology Therapy, Gastrointestinal Tumor Treatment, Head and Neck Cancer Treatment

| >180 | >110

## Oncology



**Kuo-Chen, Wei**  
M.D.

Chang Gung Memorial  
Hospital, Linko

- Vice superintendent - New Taipei City Municipal Tucheng Hospital
- Chief - Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch
- Attending physician - Department of Neurosurgery, Chang Gung Memorial Hospital, Linkou Branch

### Highlights

- Dr. Wei have participated several large international clinical trials for the primary malignant brain tumors, including the ABT-414 and the DSP-7888.
- Lead the neuro-oncology team in CGMH-LK.
- He is also involved with the development of the novel medical device for brain tumor treatment, and has completed the local phase I trial.

### Research Area(s) of Interest

Neurosurgery: intraoperative monitoring, Biosignatures of brain tumor, Drug delivery system for brain tumor: focused ultrasound for BBB opening

| >50 | >150

## Oncology



**Ming-Chin, Yu**  
M.D., Ph.D

Chang Gung  
Memorial Hospital

- Director - Department of Surgery, New Taipei Municipal TuCheng Hospital
- Chief - Division of general surgery, Chang-Gung memorial hospital, Taipei branch

### Highlights

- Dr. Yu has published more than 50 SCI papers for HCC: HCC rupture should be treated aggressively (J Surg Oncol), using copy number aberration to predict HCC outcome via OncoScan Affymetrix gene chips (2017, World Journal of Gastroenterology), and SOX4 activates CXCL12 in hepatocellular carcinoma cells to modulate endothelial cell migration and angiogenesis in vivo (Oncogene, accepted).
- He has taken the responsibilities for clinical trials in HCC since 2019, and the aims of trials were achieved to enroll the highest subject numbers for LEAP-002and Keynote-937.

### Research Area(s) of Interest

Surgery, precision medicine, target therapy, immunotherapy and TACE for hepatocellular carcinoma.

| >30 | >100

## Oncology



**Chih-Hsin, Yang**  
M.D., Ph.D

National Taiwan  
University Hospital

- Director - Department of Oncology, National Taiwan University Hospital
- Director - Cancer Administration and Coordination Center, National Taiwan University Hospital
- Director - Graduate Institute of Oncology, National Taiwan University College of Medicine

### Highlights

- Prof. Yang lead the Lung Cancer Clinical Trial Team of the National Taiwan University Hospital (1995-present). At present, this team is recognized as one of the top leading team in the field of lung cancer experimental treatment in the world. And have established many standard of care for advanced stage lung cancer.
- He is established and currently leading the Taiwan Lung Cancer Clinical Trial Consortium (TLCC).

### Research Area(s) of Interest

Oncology, Cancer clinical trial design, New anticancer drug development, Mechanism of drug resistance in cancer treatment, Regulatory science, Research ethics

| >240 | >290

## Hepatology



**Ting-Tsung, Chang**  
M.D.

National Cheng Kung  
University Hospital

- Distinguished Professor - Internal Medicine, Medical College, National Cheng Kung University
- Director - Biotechnologic Center of Hepatology, National Cheng Kung University

### Highlights

- Great contribution to hepatitis medication
- Global leading PI for one trial of Entecavir
- ACT-HBV Asia-Pacific Steering Committee Members

### Research Area(s) of Interest

Hepatitis, Hepatocellular Carcinoma, Virology, Gastroenterology

| >60 | >190



Total Number of Clinical Trials Conducted



Total Publications



Ministry of Health and Welfare  
www.mohw.gov.tw



Center for Drug Evaluation, Taiwan  
www.cde.org.tw



## Hepatology

Wan-Long, Chuang  
M.D., Ph.DKaohsiung Medical  
University Chung-Ho  
Memorial Hospital

- Vice Superintendent - Kaohsiung Medical University Chung-Ho Memorial Hospital
- Chief Editor - The Kaohsiung Journal of Medical Sciences

## Highlights

- Dr. Chuang is a reviewer and member of editorial board of several scientific journals, and the Chief Editor of the Kaohsiung Journal of Medical Sciences, and World Journal of Hepatology.
- He was the past President of the Taiwan Association for the Study of the Liver in 2010 and 2011.

Research Area(s) of Interest

Hepatobiliary and pancreatic diseases,  
viral hepatitis (particularly HBV and HCV),  
liver cirrhosis, hepatocellular carcinoma

| &gt;120 | | &gt;450

## Hepatology

Jia-Horng, Kao  
M.D., Ph.DNational Taiwan  
University Hospital

- Chief - Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital
- Professor - Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine

## Highlights

- Prof. Kao has conducted many global and local phase 2 and 3 trials for the treatment of chronic hepatitis, such as pegylated interferon and nucleos(t)ide analogues like TAF for HBV, pegylated interferon plus ribavirin and several DAAs for HCV.
- He joined several early phase clinical trials for the cure of HBV and treatment of NASH.
- Steering council of APASL now and hosted APASL annual meeting in 2012 with nearly 4000 international and local delegates.

Research Area(s) of Interest

Viral hepatitis, Hepatology, Gastroenterology

| &gt;70 | | &gt;560

## Hepatology

Long-Bin, Jeng  
M.D.China Medical  
University Hospital

- Superintendent - China Medical University Hospital, Organ Transplantation Center
- CEO - China Medical University Hospital, Cell Therapy Center
- CEO - China Medical University, Development Committee of CMU and CMUH

## Highlights

- Global leading PI of steering committee
- Top1 recruiter around the world
- Global expert for enhancing worldwide recruitment by clinical real world evidence
- Support Certican liver transplantation indication in Japan
- International speaker at international congresses
- First and corresponding author in international journals
- Preceptorship program for Asian liver transplantation team

Research Area(s) of Interest

General surgery  
Surgery of hepatobiliary pancreatic system  
Transplantation : Liver, kidney, pancreas and  
small bowel transplantation  
Cell Therapy

| &gt;20 | | &gt;340

## Hepatology

Ming-Lung, Yu  
M.D., Ph.DKaohsiung Medical  
University Chung-Ho  
Memorial Hospital

- Senior Vice President - Kaohsiung Medical University
- Academic Editor - POLS ONE
- Attending Physician - Hepatobiliary Section, Department of Internal Medicine, Kaohsiung Medical University Hospital

## Highlights

- Dr. Yu is a board-certified internist and gastroenterologist. Specializes in Hepatology. He has won numerous awards over his career.
- Editorial roles in PLoS ONE, World Journal of Gastroenterology, and Korean Journal of Hepatology.
- Editorial Board Member of "Hepatology" and "The Journal of Infectious Diseases"
- Reviewer for major international journals such as The Lancet, Annals of Internal Medicine, Clinical Microbiology Reviews, Gastroenterology, Hepatology, Gut, Journal of Hepatology, Clinical Infectious Disease, Thorax, Genome Medicine, and Journal of Infectious Diseases. Gastroenterology, Hepatology, Gut, Journal of Hepatology, Clinical Infectious Disease, Canadian Medical Association Journal, Thorax, Ontotarget, Pharmacology & Therapeutics, Scientific Reports and Journal of Infectious Diseases.

Research Area(s) of Interest

HBV, HCV, NAFLD, NASH, cirrhosis, liver cancers,  
therapeutic approach of liver disease

| &gt;60 | | &gt;320

## Hepatology

Wen-Juei, Jeng  
M.D., Ph.DChang Gung Memorial  
Hospital, Linkou Branch

- Associate Professor, Attending Physician - Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou
- Assistant Professor - Chang Gung University, College of Medicine

## Highlights

- Dr. Jeng has been main PI for HBV phase II and phase Ib trials, also NASH phase II trials.
- Advisory board for Gilead in 2018 and SpringBank in 2019 (Inarigiver, SB 9200).
- Steering committee member of global ERADICATE-B study and a member for TAsL, EAsL and AAsL. Subcommittee member of AAsLD during 2019-2020.

Research Area(s) of Interest

Hepatitis B, Viral hepatitis, Clinical hepatology

| &gt;10 | | &gt;70

## Cardiovascular Disease

Chern-En, Chiang  
M.D., Ph.DTaipei Veterans  
General Hospital

- Director - General Clinical Research Center, Taipei Veterans General Hospital
- Vice President - Taiwan Society of Cardiology
- Fellow - American College of Cardiology
- Fellow - European Society of Cardiology

## Highlights

- Dr. Chiang is has been the national lead investigator for 38 trials and sat on the steering committee for 16 trials.
- For the past 10 years, he and his team has been a hub for international collaborations by serving as a flagship site in the cardiovascular medicine-metabolism disease consortium.

Research Area(s) of Interest

Cardiovascular and metabolic disease

| &gt;50 | | &gt;280



Total Number of Clinical Trials Conducted



Total Publications

Ministry of Health and Welfare  
www.mohw.gov.twCenter for Drug Evaluation, Taiwan  
www.cde.org.tw



## Cardiovascular Disease

Chung Y. Hsu  
M.D., Ph.DChina Medical  
University Hospital

- Principal Investigator - China Medical University Hospital Clinical Trial Center
- Chief Attending Physician - China Medical University Hospital
- Endowed Chair Professor - China Medical University

## Highlights

- In the NIH-sponsored global stroke trial (ATACH-II), Prof. Hsu served as the commanding PI with 8 stroke centers in Taiwan joining. ATACH-II was published in New England Journal of Medicine (IF: 72.406) with CY Hsu as the 5th author.
- In the EXTEND trial sponsored by National Stroke Research Institute in Australia. Prof. Hsu was the commanding PI with 9 stroke centers in Taiwan joining. EXTEND was published in New England Journal of Medicine (IF: 72.406) and Lancet (IF: 53.254) with CY Hsu as the 6th author.
- The Society for Clinical Research Sites (SCRS) invited Prof. Chung Y. Hsu to serve as the SCRS Ambassador in Taiwan.

Research Area(s) of Interest

Stroke

| &gt;10 | &gt;300

## Cardiovascular Disease

Shih-Hsien, Sung  
M.D., Ph.DTaipei Veterans  
General Hospital

- Attending Physician - Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital
- Associate Professor - National Yang-Ming University

## Highlights

- Dr. Sung is a member of Taiwan Society of Internal Medicine, Taiwan Society of Cardiology, Taiwan Society of Lipids and Atherosclerosis, Taiwan Society of Critical Care Medicine, and Taiwan Society of Cardiovascular Interventions.
- He has special interests in pulmonary arterial hypertension and in minimal invasive endovascular repair of heart valves.
- He leads the Taiwan clinical network of pulmonary arterial hypertension and pioneers the transcatheter valvular intervention in Taiwan.

Research Area(s) of Interest

Cardiovascular and metabolic disease  
Pulmonary Hypertension (PAH)  
Chronic thromboembolic pulmonary  
hypertension(CTEPH)  
Transcatheter Aortic Valve Implantation (TAVI)

| &gt;40 | &gt;130

## Cardiovascular Disease

Kang-Ling, Wang  
M.D.Taipei Veterans  
General Hospital

- Attending Physician - General Clinical Research Center, Taipei Veterans General Hospital
- Attending Physician - Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital

## Highlights

- Dr. Wang has been actively involved in early phase clinical trials.
- He has involved with the clinical trial operation in the General Clinical Research Center, Taipei Veterans General Hospital, Taiwan.

Research Area(s) of Interest

Cardiovascular disease,  
Venous thromboembolism

| &gt;30 | &gt;90

## Infectious Disease

Yen-Hsu, Chen  
M.D., Ph.DKaohsiung Medical  
University Chung-Ho  
Memorial Hospital

- Superintendent -Kaohsiung Municipal Ta-Tung Hospital

## Highlights

- Dr Yen-Hsu Chen is currently the 11th chairman of the Taiwan society of internal medicine.
- He specializes in infectious disease, Dengue, Infection, HIV, Molecular biology.
- He led the dengue and zika viruses research team which consisted of researchers from KMU, Academia Sinica and NHRI for pathogenesis and viral replication.

Research Area(s) of Interest

Dengue, Infection, HIV, Molecular biology

| &gt;30 | &gt;280

## Infectious Disease

Cheng-Hsun, Chiu  
M.D., Ph.DChang Gung  
Children's Hospital

- Vice Superintendent-Chang Gung Memorial Hospital
- Professor - Department of Pediatrics, Chang Gung Children's Hospital
- Associate Professor - Department of Pediatrics, Chang Gung Children's Hospital

## Highlights

- Executive member in Steering Committee, Asian Network of Surveillance for Resistant Pathogens (ANSORP), Asian Pacific Research Foundation for Infectious Diseases (ARFID).
- Member in Steering Committee for Antimicrobial Stewardship, Pediatric Infectious Disease Society, USA (PIDS).
- Council member, Taiwan Pediatric Society
- Council member, Infectious Disease Society of Taiwan

Research Area(s) of Interest

Pediatric infectious diseases and vaccine,  
Bacterial pathogenesis,  
Bacterial genetics and genomics

| &gt;20 | &gt;440

## Infectious Disease

Li-Min, Huang  
M.D., Ph.DNational Taiwan  
University Hospital

- Director - Department of Pediatrics, National Taiwan University Hospital
- Director/ Distinguished Professor- Department of Pediatrics, College of Medicine, National Taiwan University
- Distinguished Professor - Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University

## Highlights

- Dr. Huang has established the Taiwan Pediatric Diseases Clinical Trial Consortium (TPDCTC). Since 2010, TPDCTC has already accomplished many joint researches regarding pediatric infectious diseases, and more studies about vaccine efficacy.
- The database management platform of TPDCTC has proven working after a long collaborative study of pediatric pneumonia.
- TPDCTC aims to expand from Taiwan to an international collaboration with the large data bank and species bank that will help this consortium to move to the new world of precision medicine.

Research Area(s) of Interest

Pediatrics Infectious diseases,  
Molecular Virology, HIV and AIDS, Vaccinology

| &gt;50 | &gt;380



Total Number of Clinical Trials Conducted



Total Publications

Ministry of Health and Welfare  
www.mohw.gov.twCenter for Drug Evaluation, Taiwan  
www.cde.org.tw



Infectious Disease



Wen-Sen, Lee  
M.D.

WFH  
Taipei Municipal  
Wanfang Hospital

- Associate Professor -Taipei Medical University, Department of Internal Medicine.
- Director- Taipei Municipal Wanfang Hospital, Division of Infectious Disease.

Highlights

- Participated in investigations ranging from Phase I to Phase IV studies since 2010.
- Having the successful experience in against SARS.
- Speciality:
  - Clinical infectious disease
  - Clinical Microbiology
  - Infection control
- -AIDS

Research Area(s) of Interest  
Infectious Disease

| >20 | >120

Gastroenterology



Deng-Chyang, Wu  
M.D., Ph.D

Kaohsiung Medical  
University Chung-Ho  
Memorial Hospital

- Vice Superintendent - Kaohsiung Medical University Chung-Ho Memorial Hospital

Highlights

- Dr. Wu specializes in digestive tract diseases, inflammatory bowel disease and Helicobacter pylori infection, endoscopic examination and therapy.
- He led the team of Gastroenterology Division of KMUH to join the global clinical trial of new inflammatory drug, Vedolizumab, and was the only group which participated the clinical trial in Taiwan.

Research Area(s) of Interest

Digestive Diseases, Helicobacter pylori, Endoscopy · Stem cell

| >40 | >330

Early Phase Trial



Chia-Chi, Lin  
M.D., Ph.D

National Taiwan  
University Hospital

- Director of Phase I Center-Department of Oncology, National Taiwan University Hospital
- Associate Professor-Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine

Highlights

- Prof. Lin has established one of the largest oncology phase I centers in Asia for more than 10 years.
- He played a very important role in developing novel chemotherapies ( e.g. TLC388, DS8201) and targeted therapies (e.g. BI6727, LDE225, AZD9291, TSR011, PLX3397...)
- In recent years, He is also heavily involved in developing novel immunotherapies [e.g. pembrolizumab (MK3475); spartalizumab (PDR001); tislelizumab (BGB-A317)...].

Research Area(s) of Interest  
Medical Oncology, Phase I Clinical Trials

| >150 | >110

Nephrology



Mai-Szu, Wu  
M.D.

TMUH Shuang Ho  
Hospital

- Superintendent - Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare
- Superintendent - Taipei Medical University-Hsin Kuo Min Hospital

Highlights

- Participated in investigations ranging from Phase I to Phase IV studies since 1991.
- Currently involved in the trials: Treatment of Chronic Kidney Disease (CKD), IgA Nephropathy, primary focal segmental glomerular sclerosis (FSGS) ect .
- Domestic single-center Phase I trial: Allogeneic Infusion of Adipose-Derived Stem Cells in Moderate to Severe Chronic Kidney Disease

Research Area(s) of Interest

Nephrology

| >30 | >200

Early Phase Trial



Ming-Che, Liu  
M.D., Ph.D

Taipei Medical  
University Hospital

- Director - Joint Clinical Research Center, Office of Human Research, Taipei Medical University
- Assistant Professor - Graduate Institute of Clinical Medicine, Taipei Medical University

Highlights

- Trials performed in the past five years as follow:
- International Phase I trial, Global leading PI and Publication: N201510041- MAXACALCITOL
  - Other international Phase I trials: N201803072- Carcinoma, N201602012- rheumatoid arthritis, N201508031- Peginterferon (PEG-IFN)
  - Domestic single-center Phase I trial: N201812036- MG-S-2525, N201811036
  - Phase II trial, the largest number of cases enrolled in the country: N201706060- Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult Volunteers
  - 505b2 trial: N201905023, N201811032 [A18025B1], N201809008, N201803068- (BE-NDA-T654-1701), N201802067- (BA NDA-T449-1701), N201712018

Research Area(s) of Interest  
Urology

| >100 | >10

# TAIWAN CLINICAL TRIALS

A one-stop shop that provides essential up-to-date information about Taiwan's clinical trial environment including regulations, health statistics, clinical trial centers and more.

With the support of the MOHW, Taiwan Clinical Trials is established and managed by the Center for Drug Evaluation since 2014.



TaiwanClinicalTrials.tw



Clinical Trial Centers



Ministry of Health and Welfare  
www.mohw.gov.tw



Center for Drug Evaluation, Taiwan  
www.cde.org.tw



Total Number of Clinical Trials Conducted



Total Publications